PEGylation alleviates the non-specific toxicities of Alpha-Momorcharin and preserves its antitumor efficacy in vivo

• Published in: Drug delivery Vol. 23; no. 1; pp. 95 - 100
• Main Authors: Deng, Nian-hua, Wang, Ling, He, Qian-chuan, Zheng, Jue-cun, Meng, Yao, Meng, Yan-Fa, Zhang, Chong-Jie, Shen, Fu-bing
• Format: Journal Article
• Language: English
• Published: England Taylor & Francis 02.01.2016
• Subjects: Animals; anti-tumor activity; Antineoplastic Agents, Phytogenic - pharmacokinetics; Antineoplastic Agents, Phytogenic - pharmacology; Antineoplastic Agents, Phytogenic - toxicity; Breast Neoplasms - drug therapy; Breast Neoplasms - metabolism; Chemistry, Pharmaceutical; Dose-Response Relationship, Drug; Female; Half-Life; Humans; Mammary Neoplasms, Experimental - drug therapy; Mammary Neoplasms, Experimental - metabolism; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasms, Experimental - drug therapy; Neoplasms, Experimental - pathology; PEGylation; pharmacokinetics; Polyethylene Glycols - chemistry; Rats; Rats, Sprague-Dawley; Ribosome Inactivating Proteins - pharmacokinetics; Ribosome Inactivating Proteins - pharmacology; Ribosome Inactivating Proteins - toxicity; α-MMC; α-MMC-PEG; pharmacokinetics; α-MMC-PEG; PEGylation; anti-tumor activity; α-MMC
• ISSN: 1071-7544; 1521-0464
• DOI: 10.3109/10717544.2014.905652

Alpha-Momorcharin (α-MMC) is a ribosome inactivating protein from Momordica charantia with anti-tumor activity. Previously, we had observed that modification of α-MMC with polyethylene glycol (PEG) could reduce toxicity, but it also reduces its anti-tumor activity in vitro. This study aims to investigate whether the metabolism-extended properties of α-MMC resulting from PEGylation could preserve its anti-tumor efficacy in vivo through pharmacokinetics and antitumor experiments. The pharmacokinetics experiments were conducted in rats using the TCA (Trichloroacetic Acid) method. Antitumor activity in vivo was investigated in murine mammary carcinoma (EMT-6) and human mammary carcinoma (MDA-MB-231) transplanted tumor mouse models. The results showed that PEGylation increased the plasma half-life of α-MMC in rats from 6.2-7.5 h to 52-87 h. When administered at 1 mg/kg, α-MMC-PEG and α-MMC showed similar anti-tumor activities in vivo, with a T/C% of 38.56% for α-MMC versus 35.43% for α-MMC-PEG in the EMT-6 tumor model and 36.30% for α-MMC versus 39.88% for α-MMC-PEG in the MDA-MB-231 tumor model (p > 0.05). Importantly, at the dose of 3 mg/kg, all the animals treated with α-MMC died while the animals treated with α-MMC-PEG exhibited only moderate toxic reactions, and α-MMC-PEG exhibited improved anti-tumor efficacy with a T/C% (relative tumor growth rate) of 25.18% and 21.07% in the EMT-6 and MDA-MB-231 tumor models, respectively. The present study demonstrates that PEGylation extends the half-life of α-MMC and alleviates non-specific toxicity, thereby preserving its antitumor efficacy in vivo, and a higher lever of dosage can be used to achieve better therapeutic efficacy.